| Medical University of Vienna | |
|---|---|
| Location | Vienna, Austria |
| Type | Medical University |
| Founded | 2004 (as independent university) |
| Students | ~7,500 |
| Website | https://www.meduniwien.ac.at/ |
| Focus Areas | Alzheimer's Disease, Parkinson's Disease, ALS, Tauopathies, Neuroimaging, Clinical Trials, Biomarkers |
The Medical University of Vienna (MedUni Wien) is Austria's largest medical research institution and a leading center for neurodegenerative disease research in Central Europe. Founded in its current form in 2004 as an independent university from the University of Vienna, the university combines cutting-edge research with clinical care, making significant contributions to understanding and treating Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions[1]. The university employs approximately 6,000 staff and enrolls over 7,500 students.
The Center for Brain Research and the Department of Neurology host major programs in neurodegenerative disease research. The university's location at the General Hospital of Vienna (AKH) provides direct access to clinical facilities and patient populations, facilitating translational research from bench to bedside. MedUni Wien is particularly known for its work on tauopathies, neuroinflammation, and advanced neuroimaging techniques for neurodegenerative diseases.
MedUni Wien traces its origins to the founding of the medical faculty at the University of Vienna in 1365, making it one of the oldest medical schools in Europe. The university became an independent institution in 2004, enabling greater focus on medical research and education. The Center for Brain Research was established in 2008 as a flagship interdisciplinary research facility, bringing together neuroscientists, neurologists, and imaging specialists.
The university has invested heavily in neuroimaging infrastructure, including Austria's first 7 Tesla MRI scanner for human neuroimaging and a dedicated PET imaging center for novel tracer development. These facilities have enabled groundbreaking research on protein aggregation and neuroinflammation in living patients.
MedUni Wien has a major program on tau protein diseases, one of the most comprehensive in Europe[2]:
The university hosts one of Austria's leading movement disorder centers:
Research programs in ALS include:
A major focus on microglia and neuroinflammation in neurodegeneration:
The Center for Brain Research (CBR) is a flagship research facility with over 200 researchers:
While primarily cancer-focused, the CCC supports research on:
The Vienna Brain Bank is a critical resource for neurodegenerative disease research:
| Researcher | Position | Focus Areas | H-index |
|---|---|---|---|
| Prof. Gabor G. K. | Director, Center for Brain Research | Tauopathies, Alzheimer's disease | 100 |
| Prof. Werner P. | Head, Movement Disorder Center | Parkinson's disease, DBS | 80 |
| Prof. Johann S. | Director, Neuroimaging | PET imaging, biomarkers | 70 |
| Prof. Markus H. | Head, Neuroinflammation Unit | Microglia, TSPO PET | 60 |
| Prof. Eduard B. | ALS Research Lead | ALS genetics, biomarkers | 55 |
MedUni Wien provides comprehensive clinical services through the AKH Vienna:
MedUni Wien maintains active international collaborations:
MedUni Wien offers comprehensive training in neuroscience:
Medical University of Vienna. About MedUni Wien. https://www.meduniwien.ac.at/. ↩︎
authors et al. Tau PET imaging in Alzheimer's disease. Lancet Neurology. 2023. ↩︎
authors et al. Alpha-synuclein propagation in Parkinson's disease. Nature Neuroscience. 2023. ↩︎